Lightstone Ventures’ Post

Celebrating innovation at NANBIOSIS, on World Pharmacists’ Day 💊 On #WorldPharmacistsDay, we recognize the invaluable contributions of pharmacists in patient care and groundbreaking research. This year, we're highlighting some remarkable advancements in healthcare from our researchers in NANBIOSIS: 🔬 Unit 9: Pioneering pulmonary drug delivery for diseases like asthma and COPD with innovative aerosol technology, led by Jesus Santamaria and José Luis Hueso from Universidad de Zaragoza 🔎 Unit 25: Leading cutting-edge cancer research with advanced imaging to track the effectiveness of new therapies, including noninvasive glioblastoma treatments, led by Carles Arus and Ana Paula Candiota from Universitat Autònoma de Barcelona Our researchers are driving medical innovation, shaping the future of healthcare! Learn more 👇   🔗 https://lnkd.in/dWvHETA2 #HealthcareInnovation #PulmonaryDrugDelivery #CancerResearch #NANBIOSIS #NanbiosisExpertise #CEBiomedS #CEBS #ICTSNews

Some projects take more time than others, this was definitely one of them... This study started in 2016, way before I started my PhD. It has seen several people in the lead, taken many hours of work and could only come to an end with all of these people collaborating and staying devoted until the end. I'm happy that the project is finished and it is even more rewarding that the results are quite surprising and interesting! In this study, we found that B cells negatively correlate with the anti-tumor response of the generated TIL products from NSCLC lesions, probably due to TLS formation. This is contrary to what we know so far for predicting immunotherapy response for NSCLC patients, thus not what we were expecting to find at all. Read our paper to find out our hypothesis behind this. 😉 Many thanks to everyone who has been involved in this study over the last eight years! https://lnkd.in/ezghfN6H #Sanquin #Oncode

How good are European health systems in publishing real-world data (#RWD) on #quality indicators? A new IHE report looks at the example of drug #treatment rates in advanced-stage non-small cell lung cancer (#NSCLC). As illustrated in the map, our review of published data finds a pronounced absence of reliable, comprehensive, up-to-date data. #Sweden and the #UK emerged as best-practice examples, yet even in these countries the published data are not granular enough to get a full picture of the quality of treatment provided. The review of published RWD studies also shows that recent advances in the medical treatment of NSCLC may not be fully utilized in clinical settings. It is common to observe an underuse of newer treatments options (#immunotherapy and #targetedtherapy) and an overuse of older treatment options (#chemotherapy) compared to recommendations in ESMO clinical guidelines. This report follows in the footsteps of a previous IHE report that estimated drug treatment rates in NSCLC for 12 countries and provided a qualitative analysis of reasons for sub-optimal treatment rates (Link: https://lnkd.in/dikj8USE)). It also responds to a Call to Action - Fighting lung cancer together as equals - that a group of stakeholders under the patronage of MEP Cristian-Silviu Bușoi issued in December 2022 (Link: https://lnkd.in/eD86Gpi8). 👉 Download the new IHE report here: https://lnkd.in/dJ5G78Xi

Great overview summarizing current and emerging clinical & translational data in support of neoadjuvant immunotherapy in patients with resectable dMMR & pMMR CRC. https://lnkd.in/eCMhvq-G

The groundbreaking results of the NETTER-2 trial herald a significant stride in the fight against advanced neuroendocrine tumors (NETs), particularly in the digestive system. The efficacy demonstrated by Lu 177-dotatate (Lutathera) in combination with octreotide is undeniably promising, showcasing nearly tripled progression-free survival and unprecedented tumor response rates. Led by Dr. Simron Singh, this pioneering study not only challenges existing treatment paradigms but also addresses the pressing need for effective therapies for high-grade GEP-NETs, a particularly elusive subset. However, as discussions around long-term side effects persist, including the rare occurrence of myelodysplastic syndrome (MDS), careful consideration of individual patient characteristics remains paramount. While the accessibility of Lu 177-dotatate may pose challenges in certain regions, its potential to transform patient outcomes underscores the urgency of addressing logistical barriers to ensure equitable access globally. As we navigate these pivotal findings, collaboration among clinicians, researchers, and policymakers becomes imperative to realize the full therapeutic potential of Lu 177-dotatate and advance the standard of care for individuals grappling with advanced NETs. #cancertreatment #globalhealthcareaccess #neuroendocrinetumors

Tune in later this month to our poster at ASCO-GI with the first interim results of our ADG126 plus pembrolizumab study in MSS CRC patients. Our results suggest SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target. https://loom.ly/g_zeyNM

I have changed my old mantra that clinical trials are always a good option for cancer patients. For some patients it’s about values and choices, but form who are interested in pursuing a clinical trial, the choice should be a fair one. Control arms in clinical trials should offer the current standard of care. Anything else should not be acceptable. “Physicians choice” should really be physicians choice, not a limited set of options. We celebrate the advances we have made in new drug development, but that should not be at the expense of people being randomized to inferior care. https://lnkd.in/g_sTcX8i

ctDNA guided adaptive de-escalation of TKI therapy in NSCLC “In this study, 26 patients (57%) received retreatment due to the detection of ctDNA, highlighting the importance of ctDNA analysis in identifying MRD in advanced NSCLC after TKI discontinuation. Among the 9 patients who experienced disease progression without detected ctDNA, 6 patients with brain metastasis only. This suggested the limit of detection of current technologies, particularly for some metastatic sites, such as the cerebrum.22 As ctDNA analysis platforms continue to develop, future technical advances will improve the sensitivity of ctDNA detection. An adaptive de-escalation therapeutic strategy based on high-sensitivity ctDNA analysis deserves to be verified across a broad spectrum of malignancies and anticancer agents.” #NSCLC #TKI #ctDNA #therapydeesculation #drugholiday #MRD #genomicprofiling

this adaptive de-escalation TKI strategy for patients with NSCLC is feasible in those with no lesions after LCT and a negative ctDNA test result. This might provide a de-escalation treatment strategy guided by ctDNA for the subset of patients with advanced NSCLC. #ctdna

🥼 ExThera Medical's OSCAR I Study, aimed at treating Metastatic Pancreatic Ductal Adenocarcinoma, has enroled its first patient. It will analyse the initial safety and signals of efficacy by determining the capability of the ONCObind procedure hemoperfusion filter to eliminate circulating tumour cells from the bloodstream of those patients suffering from metastatic pancreatic ductal adenocarcinoma. 👏 CEO Erin Borger shared: “This trial represents the opportunity to offer potential new hope for patients with metastatic PDAC, who currently face limited options and poor prognosis." 🔗 Read more: https://lnkd.in/dEEE5ayv 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/db58MdYp #MedicalDevices #MedicalDevice #MedicalEquipment #HealthTech #GuidedSolutions #ExecutiveSearch